Yıl: 2022 Cilt: 39 Sayı: 4 Sayfa Aralığı: 246 - 254 Metin Dili: İngilizce DOI: 10.4274/balkanmedj.galenos.2022.2022-3-26 İndeks Tarihi: 16-10-2022

Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma

Öz:
Background: miRNAs are involved in tumor pathogenesis and can therefore be determined in the primary tumor, plasma and serum, and body fluids. As in various cancers, their role in the diagnosis, prognosis, and treatment of patients with malignant pleural mesothelioma (MPM) may be important. Aims: To analyze the predictive value of miR-16-5p, miR-29c-3p, miR-31-5p, miR-125a-5p, miR-320a, miR-484 and miR-532-5p expressions for diagnosis, prognosis and response to treatment in patients with MPM. Study Design: Prospective case-control study. Methods: In the first phase of the study, blood samples were collected from 101 MPM patients before chemotherapy and from 24 healthy donors (HDs). In the second phase, the blood samples were collected from 74 MPM patients who had received chemotherapy when the best overall response and disease recurrence were determined. A quantitative real-time polymerase chain reaction was undertaken to detect the miRNA expression levels. The miRNA expression profiles of MPM patients were compared with those of HDs. The associations between the expression levels of miRNAs and prognosis and response to treatment were then evaluated. Results: All miRNAs, except miR-31-5p, were expressed differently in MPM relative to that in HDs. The expression level of miR-16- 5p decreased when compared with that of HDs, and the expression levels of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p increased when compared with that of HDs. The sensitivity and specificity values of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p for discriminating MPM from HDs were 85.9% and 59.1%, 95.1% and 62.5%, 87.1% and 79.2%, 82.2% and 58.3%, and 69.3% and 82.6%, respectively. After adjusting for the histological subtype, stage, and treatment, the miR-29c-3p, miR-125a-5p, and miR-484 were associated with longer survival. The miRNA expression levels did not change longitudinally for the determination of chemotherapy response and recurrence. Conclusion: miRNAs may be useful in diagnosing patients with MPM and provides helpful information in determining the prognosis of patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716-724. [CrossRef]
  • Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global asbestos disaster. Int J Environ Res Public Health. 2018;15:1000. [CrossRef]
  • Metintaş S, Batırel HF, Bayram H, et al. Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program. Int J Environ Res Public Health. 2017;14:1293. [CrossRef]
  • Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1-i30. [CrossRef]
  • Ak G, Metintas S, Metintas M, et al. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol. 2009;4:1425-1430. [CrossRef]
  • Vogl M, Rosenmayr A, Bohanes T, et al. Biomarkers for malignant pleural mesothelioma-a novel view on inflammation. Cancers (Basel). 2021;13:658. [CrossRef]
  • Sturchio E, Berardinelli MG, Boccia P, Zanellato M, Gioiosa S. MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma. Arch Environ Occup Health. 2020;75:471-482. [CrossRef]
  • Lo Russo G, Tessari A, Capece M, et al. MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: A literature review. Front Oncol. 2018;8:650. [CrossRef]
  • Kavitha N, Vijayarathna S, Jothy SL, et al. MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev. 2014;15:7489-7497. [CrossRef]
  • Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malignancies. Biomark Med. 2015;9:131-151. [CrossRef]
  • Truini A, Coco S, Genova C, et al. Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma. Microrna. 2016;5:12-18. [CrossRef]
  • Ak G, Tomaszek SC, Kosari F, et al. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int. 2015;2015:635748. [CrossRef]
  • Mozzoni P, Ampollini L, Goldoni M, et al. MicroRNA expression in malignant pleural mesothelioma and asbestosis: A pilot study. Dis Markers. 2017;2017:9645940. [CrossRef]
  • Schelch K, Kirschner MB, Williams M, et al. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. Mol Oncol. 2018;12:58-73. [CrossRef]
  • Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010;70:1916-1924. [CrossRef]
  • Matsumoto S, Nabeshima K, Hamasaki M, Shibuta T, Umemura T. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component. Med Oncol. 2014;31:303. [CrossRef]
  • Kirschner MB, Cheng YY, Armstrong NJ, et al. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol. 2015;9:715-726. [CrossRef]
  • Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644. [CrossRef]
  • Tsao AS, Gladish GW, Gill RR. Revised Modified RECIST Criteria in malignant pleural mesothelioma (Version 1.1): A step forward in a long race. J Thorac Oncol. 2018;13:871-873. [CrossRef]
  • Micolucci L, Akhtar MM, Olivieri F, Rippo MR, Procopio AD. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis. Oncotarget. 2016;7:58606-58637. [CrossRef]
  • Weber DG, Brik A, Casjens S, et al. Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study. BMC Res Notes. 2019;12:77. [CrossRef]
  • Bononi I, Comar M, Puozzo A, et al. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Oncotarget. 2016;7:82700-82711. [CrossRef]
  • Lamberti M, Capasso R, Lombardi A, et al. Two different serum miRNA signatures correlate with the clinical outcome and histological subtype in pleural malignant mesothelioma patients. PLoS One. 2015;10:e0135331. [CrossRef]
  • Kirschner MB, Cheng YY, Badrian B, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7:1184-91. [CrossRef]
  • Santarelli L, Strafella E, Staffolani S, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One. 2011;6:e18232. [CrossRef]
  • Weber DG, Johnen G, Bryk O, Jöckel KH, Brüning T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma--a pilot study. PLoS One. 2012;7:e30221. [CrossRef]
  • Matboli M, Shafei AE, Azazy AE, et al. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. Biomark Med. 2018;12:129-139. [CrossRef]
  • De Santi C, Melaiu O, Bonotti A, et al. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci Rep. 2017;7:3140. [CrossRef]
  • Truini A, Coco S, Nadal E, et al. Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. Oncotarget. 2017;8:68627-68640. [CrossRef]
  • Williams M, Cheng YY, Phimmachanh M, Winata P, van Zandwijk N, Reid G. Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. Cancer Drug Resist. 2019;2:1193-1206. [CrossRef
APA Metintas M, Ak G, bogar f, Metintas S, Ozbayer C (2022). Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. , 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
Chicago Metintas Muzaffer,Ak Guntulu,bogar filiz,Metintas Selma,Ozbayer Cansu Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. (2022): 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
MLA Metintas Muzaffer,Ak Guntulu,bogar filiz,Metintas Selma,Ozbayer Cansu Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. , 2022, ss.246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
AMA Metintas M,Ak G,bogar f,Metintas S,Ozbayer C Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. . 2022; 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
Vancouver Metintas M,Ak G,bogar f,Metintas S,Ozbayer C Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. . 2022; 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
IEEE Metintas M,Ak G,bogar f,Metintas S,Ozbayer C "Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma." , ss.246 - 254, 2022. 10.4274/balkanmedj.galenos.2022.2022-3-26
ISNAD Metintas, Muzaffer vd. "Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma". (2022), 246-254. https://doi.org/10.4274/balkanmedj.galenos.2022.2022-3-26
APA Metintas M, Ak G, bogar f, Metintas S, Ozbayer C (2022). Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. Balkan Medical Journal, 39(4), 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
Chicago Metintas Muzaffer,Ak Guntulu,bogar filiz,Metintas Selma,Ozbayer Cansu Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. Balkan Medical Journal 39, no.4 (2022): 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
MLA Metintas Muzaffer,Ak Guntulu,bogar filiz,Metintas Selma,Ozbayer Cansu Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. Balkan Medical Journal, vol.39, no.4, 2022, ss.246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
AMA Metintas M,Ak G,bogar f,Metintas S,Ozbayer C Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. Balkan Medical Journal. 2022; 39(4): 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
Vancouver Metintas M,Ak G,bogar f,Metintas S,Ozbayer C Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. Balkan Medical Journal. 2022; 39(4): 246 - 254. 10.4274/balkanmedj.galenos.2022.2022-3-26
IEEE Metintas M,Ak G,bogar f,Metintas S,Ozbayer C "Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma." Balkan Medical Journal, 39, ss.246 - 254, 2022. 10.4274/balkanmedj.galenos.2022.2022-3-26
ISNAD Metintas, Muzaffer vd. "Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma". Balkan Medical Journal 39/4 (2022), 246-254. https://doi.org/10.4274/balkanmedj.galenos.2022.2022-3-26